Mirador Therapeutics Inc. has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody with potential to treat ANCA-associated ...

Insmed Inc. has delivered further evidence of the advantages of its once-daily pulmonary arterial hypertension (PAH) drug ...

Eioncell Co. Ltd. and Hallym University have reported new antibody-drug conjugates (ADCs) comprising an antibody targeting kita-kyushu lung cancer antigen 1 (KK-LC-1; CT83) linked to a cytotoxic drug ...

Kyowa Kirin Co. Ltd. has identified new solute carrier family 15 member 4 (SLC15A4) inhibitors potentially useful for the treatment of autoimmune disease and lupus nephritis.

GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...

Biopharma deal value through the first half (H1) of 2026 reached $170.11 billion, surpassing every prior year in BioWorld’s ...

Indole-based compounds have been explored as antimalarial agents because they can disrupt the Plasmodium cell cycle. In a ...

Leica Biosystems GmbH, agreed to buy Statlab Medical Products in a move that will strengthen parent company Danaher Corp.'s diagnostics and anatomical pathology portfolio with a broader range of ...

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head ...

Branded Lipfendra, Merck & Co. Inc.’s oral PCSK9 inhibitor enlicitide, part of the FDA Commissioner’s National Priority ...

Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the ...

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy. Researchers at Alnylam Pharmaceuticals and ...